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Human Immunodeficiency Virus (HIV) is a blood-borne virus which is transmitted through 
direct contact with an infected mucosal membrane or bodily fluids such as blood and semen. It 






Aim: This study is therefore aimed at evaluating the serum level of alpha fetoprotein and liver 
enzymes in HIV patients undergoing antiretroviral therapy at Federal Medical Centre, Owerri. 
Materials and method: A total of one hundred and fifty subjects which comprised 50 HIV 
patients on antiretroviral therapy, 50 HIV patients not yet on antiretroviral therapy and 50 
healthy subjects as control were used in the study. The liver enzymes and alpha fetoprotein 
serum levels were determined using colorimetric end-point method and ELISA technique, 
respectively. Statistical analysis was performed on Statistical Package for Social Science 
(SPSS) windows version 20.0.Test of significance was determined using the student’s t-test 
and the statistical significance was set up at p<0.05.Results:. Results obtained showed a 
significant increase (p<0.05) in alpha fetoprotein (4.64±4.42ng/ml), Aspartate 
aminotransferase (13.3±8.10iu/L), Alanine Aminotransferase (7.58±3.56iu/L) and alkaline 
phosphatase (68.73±54.95iu/L) of the HIV positive patients when compared with to their 
controls (1.43±1.53ng/ml), (5.75±3.03iu/L), (3.85±2.33iu/L) (25.9±9.17iu/L) respectively. 
There were no significant difference (P>0.05) in the mean value of the alpha fetoprotein of 
those already in ART (5.91±5.60ng/ml) when compared with the mean value seen in those not 
on the therapy (3.36±2.10ng/ml). Also, when compared according to duration of therapy, a 
significant increase was seen at P>0.05 in all the parameters. This study inferred that long time 
use of these antiretrovirals has a damaging effect on the liver but can't possibly cause 
hepatocellular carcinoma except in the presence of other risk factors. Thus, the intake of the 
drug should be strictly under the doctor's prescription and monitoring. 
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mother-to-child transmission, which can occur during the birth process or during breastfeeding. 
Infection with the human immunodeficiency virus (HIV) causes Acquired Immunodeficiency 
Syndrome (AIDS), which affects the cells of the immune system, and destroys or impairs their 
function[1].  
The virus belongs to a class of viruses called retroviruses and more specifically, a subgroup 
called lentiviruses, or viruses that cause disease slowly[2]. 
HIV cannot replicate on its own, so in order to make new copies of itself, it must infect cells of 
the human immune system, called CD4 cells[3]. CD4 cells are white blood cells that play a 
central role in responding to infections in the body. Over time, CD4 cells are killed by HIV and 
the body’s ability to recognise and fight some types of infection begins to decline slowly losing 
its ability to fight other infections and diseases, and ultimately leading to “immune 
deficiency"[4]. Immunodeficient people are prone to opportunistic infections and cancers .There 
is no cure or vaccine currently available, but the availability of effective antiretroviral therapy 
has significantly decreased mortality and increased survival times of HIV-infected people in 
high-income countries[5] 
Antiretroviral drugs are medications for the treatment of infection by retroviruses, primarily 
HIV[6] . Different classes of antiretroviral drugs act at different stages of the HIV life cycle to 
stop HIV from replicating. Combination of several (typically three or four) antiretroviral drugs 
is known as Highly Active Anti-Retroviral Therapy (HAART) [3].The life expectancy of a 
person who carries the HIV virus is now approaching that of a person that tests negative for the 
virus, as long as they adhere to the combination of medication[6]. 
The liver is the largest internal organ and is situated in the upper right-hand side of the abdomen, 
protected by the ribs[7]. 
Although a healthy liver is important to everybody, it is especially important to people with 
HIV, not least because the liver plays an important role in how the body processes anti-HIV 
drugs and other drugs (Graham et al., 2007). 
Even though HIV drugs are intended to do our health good, the liver recognizes them as toxic 
compounds[8]. Working with the kidneys and other organs, the liver processes these drugs to 
render them safer. In the process, the liver can become “overworked,” which can lead to liver 
damage. Antiretrovirals may then raise liver enzyme levels; Aspartate aminotransferase (AST) 
Alanine aminotransferase (ALT) and Alkaline Phosphatase (ALP). These liver enzymes are 
secreted into the body fluids on elevation and are therefore used in the assessment of the liver 
function [9] 
Alpha-fetoprotein (AFP) is a plasma protein produced by the embryonic yolk sac and the fetal 
liver. AFP content in fetal serum is high and gradually decreases to the level of adults after birth 
[10]. An elevated serum alpha fetoprotein level serves as a tumor marker in identification of 
cancers[11].  
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With the availability of highly active antiretroviral treatment (HAART) in 1996, a remarkable 
decrease in HIV-related morbidity and mortality has been observed. This decline has been 
associated with a relative significant increase in morbidity and mortality related to many 
different non–HIV-related diseases, such as chronic liver diseases. Also HIV-infected patients 
are at enhanced risk of several cancers compared to the general population[12]. 
Though HIV has become a chronic condition in which progression to AIDS is increasingly rare 
since the availability of antiretroviral therapy (ART) yet non–AIDS-related causes of morbidity 
and mortality are becoming increasingly prevalent in HIV-infected patients on ART[13]. There 
is therefore the need to establish the relationship between the use of these antiretrovirals and 
alpha feto protein as well as  liver enzymes. However, the relationship of antiretroviral drugs to 
alpha feto protein and liver enzymes is not clear. 
Hence, it is of great importance to determine the status of some  alpha feto protein as well as  
liver enzymes among HIV positive subjects 
MATERIALS AND METHODS   
Experimental Design 
The subjects were grouped into 50 HIV patients who have not started receiving antiretrovial 
therapy. 50 HIV positive patients on antiretrovial therapy and 50 apparently healthy individuals 
without any evidence of HIV and thus served as control. 
Sample Collection 
Five (5) milliliters of blood sample was collected by standard venopuncture method[15] from 
each participant and was dispensed into dry bottle. This was centrifuged to get the serum for the 
analysis alpha feto protein and liver enzymes 
 
The Serum alpha feto protein was determined by enzyme linked immunoabsorbent assay 
(ELIZA). While Determination of Serum Aspartate Aminotransferase (AST) and Alanine 
Aminotransferase (ALT) were by Colorimetric end point reaction Method [15]. Determination 
of Serum Alkaline Phosphatase (ALP) by Colorimetric end point method [16] 
Statistical Analysis 
 The values were expressed as mean ± standard deviation. The significant difference between the 
mean value of control and experimental group was determined by one way analysis of variance 
(ANOVA) with post hoc t-test. P<0.05 was considered as statistically significant. 
RESULTS 
The results and analysis are shown in the tables below: 
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Table 4.1: The serum levels of AFP, AST, ALT and ALP in HIV patients and controls. 




t-value P-value     
AFP (ng/ml)         4.64±4.42  1.43±1.53   3.097 0.003  
AST (iu/L)           13.3±8.10 5.75±3.03 4.179 0.0002     
ALT  (iu/L) 7.58±3.56    3.85±2.33 3.963 0.0001    
ALP (iu/L) 68.73±54.95 25.9±9.17 3.403 0.001 
P < 0.05 = Statistically Significant 
Table 4.2: The serum levels of AFP, AST, ALT and ALP in HIV patients on ART and 
those not on ART. 
Parameters HIV patients  
on ART 
(n=20) 
HIV patients not 
on ART         
(n=20) 
t-value P-value     
AFP (ng/ml)         5.91±5.60             3.36±2.10        1.858                0.07      
AST (iu/L)           16.2±8.93             10.4±5.88        2.365 0.02      
ALT  (iu/L) 8.8±4.13              6.35±2.29        2.262                0.03      
ALP (iu/L) 96.4±57.56             41.05±34.55 3.590                0.0009 
P < 0.05 = Statistically Significant 
Table 4.3: The serum levels of AFP, AST, ALT and ALP in HIV patients on ART 
according to the duration of therapy. 
Parameters 4-8 weeks  
(n=6) 
9-12 weeks  
(n=6) 
>12 weeks  
(n=8)    
P-value  
AFP (ng/ml) 0.72±1.00     2.88±1.97    12.08±3.11     0.00      
AST (iu/L) 6.0±3.92     14.83±4.74     24.88±4.04   0.000003   
ALT (iu/L) 4.33±2.56     8.33±1.37     12.5±2.74 0.00007   
ALP (iu/L) 36.17±7.58     73.33±22.39   158.88±29.02   0.000   
P < 0.05 = Statistically Significant 
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Discussion 
HIV infection affects approximately 35 million persons worldwide. Progression to advanced 
liver disease remains a leading cause of death among HIV-infected persons. Though mortality 
from HIV complications has been dramatically reduced wherever effective combination 
antiretroviral therapy is utilized, there has been little impact on liver related mortality. Liver 
disease still remains an important contributor to morbidity and mortality among those with HIV 
infection [17] 
This study has shown that there was a significant increase (p<0.05) in the serum level of liver 
enzymes in HIV patients when compared with apparently healthy subjects (control). Further 
investigation reveals that the elevation in the liver enzymes was higher in HIV patients already 
in antiretroviral therapy. This agrees with the work of Campell [18]. which reported that liver 
enzymes elevations are frequently in HIV- infected patients, especially those treated with 
HAART. This significant increase seen in HIV patients treated with HAART could be linked to 
mitochondrial toxicity which is caused by the drug[19]. Mitochondrial toxicity,causes damage 
and a significant decrease to the mitochondria of the body cells because the drugs interfere with 
the enzyme needed in the production of mitochondria which could manifest as lactic acidosis, in 
which there is a build-up of lactic acid in the tissues of the body leading to loss of energy, organ 
failure, and eventually death [20]. 
Some increases in liver enzymes were also observed in some HIV patients not yet on ART 
which is in agreement with other works[21]. This may be due to direct inflammation induced by 
the HIV virus on the liver cell. It may also be due to gall bladder disease, alcohol and infection 
with bacterial or other opportunistic agents since viral hepatitis coinfected patients were 
excluded. 
Alpha fetoprotein is a sensitive marker employed in the diagnosis of hepatocellular carcinoma. It 
is usually produced whenever liver cells are regenerating with values between 100-350 ng/ml 
suggesting hepatocellular carcinoma. Hepatocellular carcinoma (HCC) is a concern among 
individuals with human immunodeficiency virus (HIV) infection and acquired 
immunodeficiency syndrome (AIDS). It was observed from this study that there were slight 
increases in the level of AFP in HIV patients on ART, but wasn't significant when compared 
with those not on ART. This agrees with the work of Abelev[23]  which states that Serum AFP 
levels may also be raised in chronic liver disease with high levels of hepatocyte regeneration but 
remain low in the majority of patients with cirrhosis in the absence of HCC, thus, AFP levels 
could still be low even when the liver enzymes are elevated. 
The insignificant rise in AFP of HIV patients on ART when compared with those not yet on 
ART proves that the use of antiretrovirals could reduce the risk of AIDS-defining cancers 
(ADC). HIV infection leads to a weakened immune system and a lower number, or count, of 
CD4+ T cells that help fight infection. This makes it more likely that people living with HIV 
will be infected with cancer-causing viruses, such as human papillomavirus and Kaposi sarcoma 
herpesvirus. Treatment with combination antiretroviral treatment (cART), which means using 
more than 1 drug to fight HIV infection and maintain the immune system, leads to reduced risk 
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of infections and HIV-associated cancers such as Kaposi sarcoma and non-Hodgkin lymphoma 
[24]. They suggested from their study that antiretrovirals may confer additional anti-cancer 
benefits other than maintaining immune function and went further to state that protease inhibitor 
(PI) agents have been shown to confer a broad-spectrum of anti-cancer properties. 
The risk of some non-AIDS defining malignancies (NADM) which may likely occur in HIV 
positive persons could be unrelated to ART use and rather attributed to coinfection with hepatitis 
virus, as this poses a higher risk of developing liver cancer. Also smoking, alcoholism and 
tobacco use could as well be causative factors. 
In Conclusion this study shows that long time administration of antiretroviral drugs could be 
deleterious to the basic functions of the liver as there is a significant increase in the level of the 
alkaline phosphatase and transaminases which indicates liver damage. This effect is of course 
expected to be higher in HIV positive patients who already have liver damage from other 
sources before commencing the therapy. Also this antiretroviral drugs tend to reduce the risk of 
AIDS-defining cancers (ADC) expected in HIV positive patients, by boosting the immune 
system, and this could be helpful if the therapy in commenced early enough. The basic claim of 
high risk of cancers, mostly NADMs, could be attributed to other factors mostly, co infection 
with hepatitis virus. 
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